1. Clinical features of COVID-19 by SARS-CoV-2 Gamma variant: A prospective cohort study of vaccinated and unvaccinated healthcare workers
- Author
-
Flavia C. S. Sales, Igor C. Borges, Pamela S Andrade, Ingra Morales Claro, Ester Cerdeira Sabino, Carolina S. Lazari, Aluísio Augusto Cotrim Segurado, Ana Rubia Guedes, Antonio Santos Barboza, Maria Cassia Mendes-Correa, Mariana Deckers Leme, Silvia Figueiredo Costa, Esper G. Kallas, Alessandra Luna-Muschi, Fernando Liebhart Maia, Elizabeth de Faria, Alberto José da Silva Duarte, and Anna S. Levin
- Subjects
Microbiology (medical) ,2019-20 coronavirus outbreak ,medicine.medical_specialty ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,SARS-CoV-2 ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,COVID-19 ,Antibodies, Viral ,Infectious Diseases ,Internal medicine ,Health care ,medicine ,Humans ,business ,Prospective cohort study ,Letter to the Editor ,BNT162 Vaccine - Abstract
The emergence of new variants of concern (VOCs) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) around the world significantly complicated the exit from Coronavirus disease 2019 (COVID-19) pandemic. The aim of this study was to evaluate the serum neutralizing activity of three cohorts.BNT162b2-elicited serum (N = 103), candidates as hyper-immune plasma donors (N = 90) and patients infected with the SARS-CoV-2 P1 variant (N = 22) were enrolled. Three strains of SARS-CoV-2 have been tested: 20A.EU1, B.1.1.7 (alpha) and P.1 (gamma). Neutralizing antibodies (NT-Abs) titers against SARS-CoV-2 were evaluated.B.1.1.7 and P.1 are less efficiently neutralized by convalescent wild-type infected serums if compared to 20A.EU1 strain (mean titer 1.6 and 6.7-fold lower respectively). BNT162b2 vaccine-elicited human sera show an equivalent neutralization potency on the B.1.1.7 but it is significantly lower for the P.1 variant (mean titer 3.3-fold lower). Convalescent P.1 patients are less protected from other SARS-CoV-2 strains with an important reduction of neutralizing antibodies against 20A.EU1 and B.1.1.7, about 12.2 and 10.9-fold, respectively.BNT162b2 vaccine confers immunity against all the tested VOCs, while previous SARS-CoV-2 infection may be less protective.
- Published
- 2022
- Full Text
- View/download PDF